Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis

Kazutaka Kamiya, Kimiya ShimizuDepartment of Ophthalmology, University of Kitasato School of Medicine, JapanAbstract: We report on a patient in whom the use of antiglaucoma drugs has been beneficial for the attainment of monovision after laser in situ keratomileusis (LASIK).A 57-year-old woman undergoing LASIK complained of blurred vision in the right eye.After a successful Baby Bouncer trial of monovision with contact lenses, antiglaucoma drugs (2.

5% nipradilol) were administered topically to the right eye twice a day to establish monovision.In the right eye, the manifest refraction was changed from −4.0, −1.

0 × 80, with an uncorrected visual acuity (UCVA) of 0.3 for near vision before treatment, to −2.5, −1.

0 × 80, with an UCVA of 0.9 for bondage_leather near vision after treatment, while, in the left eye, it was 0, −1.0 × 100, with an UCVA of 0.

9 for far vision.Binocular UCVA was improved from 0.3 for near and 0.

9 for distance vision before treatment, to 0.9 for near and 1.0 for distance vision after treatment.

No complications were observed and the manifest refraction remained stable during the 6-month follow-up period.The use of antiglaucoma drugs may be helpful for the achievement of monovision by reduction of myopic regression after LASIK.Keywords: antiglaucoma drugs, regression, monovision, LASIK.

Leave a Reply

Your email address will not be published. Required fields are marked *